NEW HEMOFARM PREPARATIONS TO APPEAR SOON

active component, the great proportion of the active component in the tablet mass. Following successful selection of the
most optimum formulation and production technique based on laboratory research, and followed by stability results,
research was conducted also of the bioequivalence of the dose of 100 mg. In vitro and in vivo tests proved that our
product was bioequivalent with the originator, under the patented name Cozaar, more precisely with the product
registered on the German market under the name Lorzaar film tablets of the producer Merck Sharp & Dohme.
The following diagram shows the results of the in vitro tests of the release of the active component for our and the original
product:
The efficiency, safety and quality of our generic product
has been confirmed through all development phases by
excellent results in the physical-chemical and biologicalmedical
researches. The trend of such good results
continued in the first transfer phase in the production, so
that we expect positive opinions and release of the first
batch by the Agency for Medicaments.
Hemofarm Institute
Staša Vuković
New Product Development Project Manager
R&D Department
STADA R&D MEETING IN VRŠAC
35 representatives of all business units of the STADA group stayed in Vršac from September 17 to 19 in the aim of
attending the regular half-yearly R&D meeting, which was held in hotel Villa Breg and was hosted by our company.
Considering the significance of the meeting at which the production portfolio was defined for the whole STADA group, our
president Mr. Miodrag Babić, vice-president Mr. Nikola Stanković and the executive vice-president Miss Sonja Pejović
took also part. Mr. Babić made a statement to the attendants at the very beginning of the meeting, wishing them welcome
and successful work and then he made a brief presentation about Hemofarm. Our president pointed out that Hemofarm
was a company in which medicaments were developed and produced to be distributed throughout Europe and he invited
the participants to visit our plants on the second day so as to get assured about the good equipment in all of our plants and
laboratories, but also about the expertise and competence of our staff.
Mr. Christof Schumann, member of the STADA group board and the R&D directors Miss Sigrid Dienel and Mr. Michael
Wolf-Pflugmann presided over the working part of the meeting. Consideration was given to the status of the earlier defined
development projects and new projects were proposed during the whole day of work. It was maintained once again that
under the conditions of the ever increasing market competition there is a great pressure on the R&D, which must provide
new products using the available resources, but also strategic approaches. It was pointed out that STADA got
development facilities with the acquisition of Hemofarm, which will enable more and more new products to be developed
in its own laboratories, whereby better control over projects is achieved, and later better management of the production
costs. New projects which would be developed in the Hemofarm institute were defined in this sense, with the intention to
register and place them on all markets on which STADA operates.
A visit to the Hemofarm production facilities was organized on the second day, whereby all guests expressed sincere
satisfaction with what they saw. They also praised the excellent organization for which the Hemofarm Institute and the
president’s cabinet were in charge of and expressed a wish to to gather again in our town.
Vjera Pejanović
Hemofarm Institute Director